U.S. Residential REITs Stock News

Investors may be wondering if Box is starting to look like a value opportunity after a rough patch, or if the market is rightly cautious about the stock at around US$22.82. The share price has been under pressure, with a 0.6% move over the last week, a 13.8% decline over 30 days, a 20.8% decline year to date, and a 31.1% decline over the past year. However, the 5 year return sits at 21.7%. Recent coverage around Box has focused on its position as a listed software player and how investors...

In February 2026, Gentherm reported fourth‑quarter 2025 earnings showing net income falling to US$2.99 million from US$15.32 million a year earlier, while quarterly revenue of about US$382.79 million came in ahead of expectations. Alongside weaker profitability, Gentherm issued product revenue guidance of US$1.5 billion to US$1.6 billion for 2026 and US$1.7 billion for 2027, highlighting its ambition to grow beyond automotive into medical and other precision thermal applications. We’ll now...

If you are wondering whether Wolverine World Wide at around US$17.58 is offering real value or just looks cheap on the surface, you are not alone. The stock has pulled back over the short term, with a 2.9% decline over 7 days and a 2.4% decline over 30 days, yet it still shows a 19.7% return over 1 year and 14.4% over 3 years, compared with a 42.3% decline over 5 years. Recent attention on Wolverine World Wide has focused on its long term share price pattern. The stronger 1 year and 3 year...

DigitalOcean Holdings FY 2025 Earnings Snapshot DigitalOcean Holdings (DOCN) has wrapped up FY 2025 with Q4 revenue of US$242.4 million and basic EPS of US$0.28, capping off a year in which trailing twelve month revenue reached US$901.4 million and EPS came in at US$2.83. The company has seen revenue move from US$780.6 million to US$901.4 million on a trailing twelve month basis, while EPS shifted from US$0.92 to US$2.83, with reported earnings growth helped by a very large year over year...

Earlier in February 2026, NeoGenomics launched RaDaR ST, a high-sensitivity circulating tumor DNA assay for molecular residual disease detection, supported by Medicare approval for initial indications and backed by clinical and real-world data across select cancers. The company also introduced PanTracer Pro to streamline complex molecular testing workflows and reported higher quarterly sales with a smaller net loss, highlighting growing adoption of newer, higher-value oncology...

Why IDEX (IEX) is on investors’ radar today IDEX (IEX) is drawing attention after a period of steady share price movement, with recent returns and current valuation metrics prompting investors to reassess how the company’s fundamentals line up with its current price. See our latest analysis for IDEX. At a share price of $208.45, IDEX has seen steady momentum recently, with a 30-day share price return of 6.75% and a 90-day share price return of 19.96%. The 1-year total shareholder return of...

If you are wondering whether Bruker is priced attractively right now, you are not alone, especially with sentiment around the stock shifting recently. The share price closed at US$39.77, with a 4.3% gain over the last 7 days, set against returns of a 21.0% decline over 30 days, a 17.3% decline year to date, and a 21.6% decline over 1 year, as well as 41.7% and 35.1% declines over 3 and 5 years respectively. These mixed shorter term and longer term returns have put more attention on what...

Why Realty Income is on investors’ radar today Realty Income (O) is drawing fresh interest after recent share price moves, with the stock last closing at $66.52. For income focused investors, that prompts a closer look at its current profile. See our latest analysis for Realty Income. Recent moves fit into a stronger run, with a 30-day share price return of 9.52% and a 90-day share price return of 16.42%, while the 1-year total shareholder return of 25.07% points to building momentum around...

Earlier this week, Tenable Holdings, a cybersecurity and vulnerability management provider, came under pressure after the White House announced plans to lift global tariffs to 15%, sparking renewed concern about trade policy and its knock-on effects for technology and software firms. At the same time, investors are weighing Tenable’s ongoing profitability and liquidity challenges against sector worries that rapid advances in artificial intelligence could reshape demand for traditional...

If you are wondering whether TG Therapeutics at around US$30.51 is priced attractively or already baking in a lot of optimism, you are in the right place. The stock has returned 5.0% over the last 7 days, is down 2.2% over 30 days, and shows mixed longer term results with a 4.2% return year to date, 4.5% over 1 year, 90.4% over 3 years, and a 32.0% decline over 5 years. These moves sit against a backdrop of ongoing interest in TG Therapeutics as a biotechnology name, with investors watching...

In recent weeks, Flutter Entertainment responded to sector pressure after rival DraftKings issued cautious 2026 revenue guidance, prompting investors to reassess U.S. online betting prospects and competitive positioning. Flutter’s leadership emphasized FanDuel’s 47% U.S. market share and the breadth of its international portfolio, underlining how product innovation such as FanDuel Predict and geographic diversification underpin its business case. We’ll now explore how Flutter’s reaffirmed...

Ivanhoe Electric (IE) has come back into focus after reporting full year 2025 results, with sales of US$3.24 million and a net loss of US$105.87 million, alongside a narrower basic loss per share. See our latest analysis for Ivanhoe Electric. The latest earnings report appears to be one of the key reference points for investors. The 1 day share price return of 5.07% and 7 day share price return of 5.96% followed a 30 day share price return decline of 17.62%. The 1 year total shareholder...

Stock performance check in on Federal Agricultural Mortgage Federal Agricultural Mortgage (AGM) has drawn attention after a mixed run in its share price, with a 1 day gain of 1.7% but declines over the past week, month, and past 3 months. For investors tracking longer horizons, the stock shows a year to date total return of about a 10.3% decline and a 1 year total return of roughly a 19.9% decline, alongside reported annual revenue growth of 15.4% and net income growth of 8.7%. See our latest...

Moody's (NYSE:MCO) has set up a new regional headquarters in Riyadh, Saudi Arabia. The move is part of the company’s plan to support the Kingdom’s capital markets and its broader Middle East presence. The Riyadh hub aligns with Saudi Arabia’s Vision 2030 initiative and reflects Moody's focus on geographical expansion. Moody's is known for its credit ratings, research, and risk analysis, which are widely used by investors and issuers to assess creditworthiness and market conditions. By...

Twist Bioscience, NasdaqGS:TWST, has entered a co exclusive licensing agreement with Invenra Inc. for Invenra's B Body bispecific antibody platform. The deal expands Twist's antibody discovery services and includes an equity investment and licensing terms that share economics between the two companies. This move adds bispecific antibody capabilities to Twist's existing biologics discovery tools, broadening the range of programs it can support for biotech and pharma customers. Twist...

How D.R. Horton Stock Has Been Performing D.R. Horton (DHI) has seen mixed recent returns, with a small 0.2% decline over the past day and a 1.4% pullback over the past week, alongside a gain over the past month. Over longer periods, the stock shows a 4.6% return over the past 3 months, 12.5% year to date, and 25.6% over the past year, with multi year total returns that are also positive. See our latest analysis for D.R. Horton. At a share price of $163.95, D.R. Horton’s 8.9% 1 month share...

What Teradata’s recent returns signal for investors Teradata (TDC) has delivered mixed share price moves, with a roughly 6.8% gain over the past day, a 7.9% decline over the past week, and positive returns over the past month and past 3 months. At a last close of $30.03, the company has a 1 year total return of about 23.6%. Its 3 year and 5 year total returns are both negative, which may catch the eye of investors comparing shorter and longer time frames. See our latest analysis for...

In February 2026, Safehold Inc. reported fourth-quarter and full-year 2025 results showing modest increases in sales, revenue, net income, and earnings per share, and confirmed that no shares were repurchased under the buyback program announced in February 2025. Alongside this, Safehold expanded its ground lease portfolio to 143 assets worth about US$6.50 billion and secured a new US$2.00 billion unsecured revolving credit facility, meaningfully increasing its financial flexibility to...

If you are trying to work out whether Caris Life Sciences at around US$18.20 is a bargain or a value trap, you are in the right place. The stock has been under pressure recently, with a 12.5% decline over the last 7 days, a 27.2% decline over the last 30 days, and a 32.5% decline year to date. Recent attention around Caris Life Sciences has focused on its position in the pharmaceuticals and biotech space and how investors are reassessing risk in the sector. This backdrop helps explain why...

If you are wondering whether Danaos is still good value after its recent run, you are in the right place. This article focuses squarely on what you are paying for each dollar of the business. The stock last closed at US$111.57, with returns of 4.0% over 7 days, 10.8% over 30 days, 17.1% year to date, 41.5% over 1 year and 116.4% over 3 years. These figures naturally raise questions about how much upside or risk is now priced in. Recent coverage of Danaos has highlighted its role in the...

If you are wondering whether Inspire Medical Systems' share price now reflects good value or lingering risk, you are not alone. The stock last closed at US$57.72, with returns of 4.4% decline over 7 days, 27.3% decline over 30 days, 37.4% decline year to date, 68.8% decline over 1 year, 77.8% decline over 3 years and 76.1% decline over 5 years. Recent coverage has focused on how the share price pullback has reshaped expectations around the company and the sleep apnea treatment market it...

If you are wondering whether Nicolet Bankshares is still reasonably priced after its strong run, this article will walk through what the current share price might be implying about its value. The stock recently closed at US$156.96, with returns of 11.1% over the last 30 days, 30.3% year to date, and 34.5% over the past year, while the 3 year and 5 year returns sit at 117.7% and 110.4% respectively. These figures may change how you think about risk and reward from here. Recent coverage of...

Concentra Group Holdings Parent: Recent Moves In Context With no single headline event driving attention to Concentra Group Holdings Parent (CON), investors are focusing on how its recent share performance and financial profile fit into the occupational health services story. See our latest analysis for Concentra Group Holdings Parent. At a share price of $23.41, Concentra Group Holdings Parent has paired a 1 month share price return of 8.63% with a year to date share price return of 20.61%...

In February 2026, Neurocrine Biosciences reported that fourth-quarter 2025 revenue rose to US$805.5 million and net income to US$153.7 million, with full-year revenue reaching US$2.86 billion and net income US$478.6 million, alongside higher basic and diluted earnings per share from continuing operations versus 2024. The company also issued 2026 guidance calling for INGREZZA net product sales of US$2.70 billion to US$2.80 billion, underscoring the central role of this flagship therapy in...